PL396319A1 - Pharmaceutical formulation for the treatment of herpes simplex virus infection and application of the formulation - Google Patents
Pharmaceutical formulation for the treatment of herpes simplex virus infection and application of the formulationInfo
- Publication number
- PL396319A1 PL396319A1 PL396319A PL39631911A PL396319A1 PL 396319 A1 PL396319 A1 PL 396319A1 PL 396319 A PL396319 A PL 396319A PL 39631911 A PL39631911 A PL 39631911A PL 396319 A1 PL396319 A1 PL 396319A1
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- formulation
- herpes simplex
- simplex virus
- virus infection
- Prior art date
Links
- 208000009889 Herpes Simplex Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 abstract 2
- 150000001450 anions Chemical class 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 241000700584 Simplexvirus Species 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000007864 aqueous solution Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 150000007522 mineralic acids Chemical class 0.000 abstract 1
- 150000007524 organic acids Chemical class 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 abstract 1
- 239000000725 suspension Substances 0.000 abstract 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Preparat farmaceutyczny do leczenia zakażenia wirusem herpes simplex, w którym składnik aktywny stanowi zawiesina nanocząstek srebra o wielkości od 1 do 100 nm w wodnym roztworze zawierającym mieszaninę dopuszczalnych farmaceutycznie anionów co najmniej jednej soli kwasu organicznego i/lub anionów co najmniej jednej soli kwasu nieorganicznego, przy czym udział nanocząstek srebra w preparacie wynosi od 0,005 do 5% wag., udział roztworu wynosi od 0,005 do 5% obj., a udział nośnika od 95 do 99,995% obj.. Wynalazek dotyczy także zastosowania preparatu do wytwarzania leku do zapobiegania i leczenia zakażenia wirusem herpes simplex.Pharmaceutical preparation for the treatment of herpes simplex virus infection, in which the active ingredient is a suspension of silver nanoparticles with a size of 1 to 100 nm in an aqueous solution containing a mixture of pharmaceutically acceptable anions of at least one salt of an organic acid and/or anions of at least one salt of an inorganic acid, with wherein the proportion of silver nanoparticles in the preparation is from 0.005 to 5% by weight, the proportion of the solution is from 0.005 to 5% by volume, and the proportion of the carrier is from 95 to 99.995% by volume. The invention also relates to the use of the preparation for the manufacture of a medicament for the prevention and treatment of infection herpes simplex virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL396319A PL237937B1 (en) | 2011-09-13 | 2011-09-13 | Pharmaceutical formulation for the treatment of herpes simplex virus infection and application of the formulation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PL396319A PL237937B1 (en) | 2011-09-13 | 2011-09-13 | Pharmaceutical formulation for the treatment of herpes simplex virus infection and application of the formulation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL396319A1 true PL396319A1 (en) | 2013-03-18 |
| PL237937B1 PL237937B1 (en) | 2021-06-14 |
Family
ID=47846451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL396319A PL237937B1 (en) | 2011-09-13 | 2011-09-13 | Pharmaceutical formulation for the treatment of herpes simplex virus infection and application of the formulation |
Country Status (1)
| Country | Link |
|---|---|
| PL (1) | PL237937B1 (en) |
-
2011
- 2011-09-13 PL PL396319A patent/PL237937B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PL237937B1 (en) | 2021-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502628B1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
| MX2015016344A (en) | Imidazopyrrolidinone derivatives and their use in the treatment of disease. | |
| MX2015016421A (en) | Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease. | |
| TR201904455T4 (en) | 1,2,4-triazoles and their uses as nuclear transport modulators. | |
| EA201590371A1 (en) | 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS | |
| GB2495676A (en) | Use of binders for manufacturing storage stable formulations | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| UA112296C2 (en) | DRY POWDER PREPARATION CONTAINING PHOSPHODIESTERASE INHIBITOR | |
| PH12014501545A1 (en) | Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof | |
| MY180145A (en) | Cenicriviroc compositions and methods of making and using the same | |
| EP3069720A8 (en) | Pharmaceutical composition containing glutarimide derivatives, and application thereof for treating eosinophilic diseases | |
| MX2015016425A (en) | Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease. | |
| JP2013538853A5 (en) | ||
| BR112014009242A8 (en) | pharmaceutical nanosuspension | |
| WO2015100348A8 (en) | Keloid reduction using topical allantoin | |
| SI2729474T1 (en) | (THIENO(2,3-b)(1,5)BENZOXAZEPIN-4-YL)PIPERAZIN-1-YL COMPOUNDS AS DUAL ACTIVITY H1 INVERSE AGONISTS/5-HT2A ANTAGONISTS | |
| PL396319A1 (en) | Pharmaceutical formulation for the treatment of herpes simplex virus infection and application of the formulation | |
| MX2014015096A (en) | Crustacean feed. | |
| TW201129660A (en) | Dermal absorption agent comprising felbinac | |
| EP2842938A4 (en) | NOVEL BETA-ALANINE DERIVATIVES, THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME AS ACTIVE INGREDIENT | |
| TR200802061A2 (en) | Pharmaceutical formulation containing highly active ingredient. | |
| WO2010027189A3 (en) | A new use for homoisoflavanone or a salt thereof | |
| EA201500366A1 (en) | APPLICATION OF 1-ADAMANTYLETYLOXY-3-MORFOLINO-2-PROPANOL OR ITS PHARMACEUTICALLY ADOPTABLE SALTS IN PHARMACEUTICAL COMPOSITIONS AS A NEURORTHINOPROTECTOR | |
| UA80243U (en) | Drug delivery system | |
| TH138424A (en) | A dry powder formulation containing an anti-muscarinic drug. |